CL2007002689A1 - Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. - Google Patents

Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.

Info

Publication number: CL2007002689A1
Authority: CL; Chile
Prior art keywords: compounds; cardiac; carboxamida; renine; piperidin
Prior art date: 2006-09-18

Application number

CL200702689A

Other languages

English (en)

Inventor

John J Claremon David Baldwin

Original Assignee

Vitae Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-18

Filing date

2007-09-14

Publication date

2008-04-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38786973&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007002689(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-09-14 Application filed by Vitae Pharmaceuticals Inc filed Critical Vitae Pharmaceuticals Inc

2008-04-18 Publication of CL2007002689A1 publication Critical patent/CL2007002689A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrane Compounds (AREA)
Hydrogenated Pyridines (AREA)

CL200702689A 2006-09-18 2007-09-14 Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. CL2007002689A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US84529106P	2006-09-18	2006-09-18

Publications (1)

Publication Number	Publication Date
CL2007002689A1 true CL2007002689A1 (es)	2008-04-18

Family

ID=38786973

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200702689A CL2007002689A1 (es)	2006-09-18	2007-09-14	Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.

Country Status (22)

Country	Link
US (2)	US8198453B2 (es)
EP (2)	EP2074108B3 (es)
JP (1)	JP5331695B2 (es)
KR (1)	KR20090064582A (es)
CN (1)	CN101528723B (es)
AR (1)	AR062797A1 (es)
AU (1)	AU2007297729C1 (es)
BR (1)	BRPI0718460A2 (es)
CA (1)	CA2663263A1 (es)
CL (1)	CL2007002689A1 (es)
DK (1)	DK2074108T3 (es)
ES (1)	ES2400009T7 (es)
HR (1)	HRP20130144T4 (es)
MX (1)	MX2009002740A (es)
NZ (1)	NZ575803A (es)
PE (1)	PE20080843A1 (es)
PL (1)	PL2074108T6 (es)
PT (1)	PT2074108E (es)
RS (1)	RS52679B (es)
SI (1)	SI2074108T1 (es)
TW (1)	TWI403510B (es)
WO (1)	WO2008036247A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2007003858A (es) *	2004-10-07	2007-12-11	Vitae Pharmaceuticals Inc	Diaminoalcanos inhibidores de proteasa asparticas.
TWI411607B (zh)	2005-11-14	2013-10-11	Vitae Pharmaceuticals Inc	天門冬胺酸蛋白酶抑制劑
ATE520690T1 (de) *	2006-09-18	2011-09-15	Vitae Pharmaceuticals Inc	Piperidinderivate als renin-inhibitoren
CL2007002689A1 (es)	2006-09-18	2008-04-18	Vitae Pharmaceuticals Inc	Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
US20100160424A1 (en) *	2007-06-20	2010-06-24	Baldwin John J	Renin inhibitors
EP2167609A1 (en) *	2007-06-20	2010-03-31	Vitae Pharmaceuticals, Inc.	Renin inhibitors
JP2011525488A (ja) *	2008-06-20	2011-09-22	ヴァイティーファーマシューティカルズ，インコーポレイテッド	レニン阻害剤およびその使用方法
US20100010228A1 (en) *	2008-06-26	2010-01-14	Vitae Pharmaceuticals, Inc.	Process for the asymmetric reduction of 3-benzoylpiperidines
US20110112145A1 (en) *	2008-06-26	2011-05-12	Nicole Marie Deschamps	Salts Of Methyl 2-((R))-(3-Chlorophenyl)((R)-1-((S)-2-(Methylamino)-3((R)-tetrahydro-2H-Pyran-3-YL)Propylcarbamoyl)Piperidin-3-YL)Methoxy)Ethylcarbamate
CA2835771C (en)	2009-03-18	2017-01-24	Incarda Therapeutics, Inc.	Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AU2016256776B2 (en) *	2009-03-18	2018-04-12	Incarda Therapeutics, Inc.	Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AU2013248242B2 (en) *	2009-03-18	2016-08-18	Incarda Therapeutics, Inc	Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AR077692A1 (es) *	2009-08-06	2011-09-14	Vitae Pharmaceuticals Inc	Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
SG11201805788WA (en)	2016-02-01	2018-08-30	Incarda Therapeutics Inc	Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
CA3060702A1 (en)	2017-05-10	2018-11-15	Incarda Therapeutics, Inc.	Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2019183470A2 (en)	2018-03-22	2019-09-26	Incarda Therapeutics, Inc.	A novel method to slow ventricular rate
US11020384B2 (en)	2019-08-01	2021-06-01	Incarda Therapeutics, Inc.	Antiarrhythmic formulation
CN117567292A (zh) *	2023-12-01	2024-02-20	江苏宝众宝达药业股份有限公司	一种制备高纯度5-氯-2-甲基苯胺的方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3071618A (en)	1956-02-02	1963-01-01	Pfizer & Co C	Diquaternary ammonium salts of n, n, n', n'-tetra substituted alkylene diamines
GB1351761A (en)	1971-02-04	1974-05-01	Wilkinson Sword Ltd	Substituted p-menthane carboxamides and compositions containing them
US4136163A (en)	1971-02-04	1979-01-23	Wilkinson Sword Limited	P-menthane carboxamides having a physiological cooling effect
JPS5115098A (ja)	1974-07-26	1976-02-06	Asahi Chemical Ind	Akurirukeiseniseihinno shorihoho
US4826689A (en)	1984-05-21	1989-05-02	University Of Rochester	Method for making uniformly sized particles from water-insoluble organic compounds
US4594343A (en)	1984-10-19	1986-06-10	Shanklin Jr James R	1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles
GB8810067D0 (en)	1988-04-28	1988-06-02	Ucb Sa	Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides
FR2634376B1 (fr)	1988-07-21	1992-04-17	Farmalyoc	Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US4908372A (en)	1988-10-13	1990-03-13	Merrell Dow Pharmaceuticals Inc.	Antihistaminic piperidinyl benzimidazoles
IT1227626B (it)	1988-11-28	1991-04-23	Vectorpharma Int	Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5696270A (en)	1989-05-23	1997-12-09	Abbott Laboratories	Intermediate for making retroviral protease inhibiting compounds
RU2147875C1 (ru)	1990-05-11	2000-04-27	Пфайзер Инк.	Способ и композиция для снижения кровяного давления и лечения застойной сердечной недостаточности у млекопитающего
US5821232A (en)	1990-05-11	1998-10-13	Pfizer Inc.	Synergistic therapeutic compositions and methods
DE4018070A1 (de)	1990-06-06	1991-12-12	Bayer Ag	Morpholinoharnstoff-derivate
IT1243390B (it)	1990-11-22	1994-06-10	Vectorpharma Int	Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
WO1992010491A1 (en)	1990-12-14	1992-06-25	Merrell Dow Pharmaceuticals Inc.	Antiallergic compounds
US5552160A (en)	1991-01-25	1996-09-03	Nanosystems L.L.C.	Surface modified NSAID nanoparticles
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
EP0626968B1 (en)	1992-02-13	2001-09-26	Merrell Pharmaceuticals Inc.	Piperidinyl thiacyclic derivatives
WO1993025190A1 (en)	1992-06-10	1993-12-23	Eastman Kodak Company	Surface modified nsaid nanoparticles
NZ248813A (en)	1992-11-25	1995-06-27	Eastman Kodak Co	Polymeric grinding media used in grinding pharmaceutical substances
US5346702A (en)	1992-12-04	1994-09-13	Sterling Winthrop Inc.	Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en)	1992-12-04	1994-03-29	Sterling Winthrop Inc.	Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en)	1992-12-09	1994-04-12	Sterling Winthrop Inc.	Method to reduce particle size growth during lyophilization
US5340564A (en)	1992-12-10	1994-08-23	Sterling Winthrop Inc.	Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en)	1992-12-11	1994-08-09	Sterling Winthrop Inc.	Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en)	1992-12-15	1995-07-04	Eastman Kodak Company	Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en)	1992-12-16	1994-10-04	Sterling Winthrop Inc.	Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en)	1994-06-28	1996-12-24	Nanosystems L.L.C.	Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
EP0773921B1 (en)	1994-07-29	1999-12-01	Abbott Laboratories	Process for the preparation of a substituted 2.5-diamino-3-hydroxyhexane
US6162927A (en)	1994-08-19	2000-12-19	Abbott Laboratories	Endothelin antagonists
US5767144A (en)	1994-08-19	1998-06-16	Abbott Laboratories	Endothelin antagonists
US6946481B1 (en)	1994-08-19	2005-09-20	Abbott Laboratories	Endothelin antagonists
US5585108A (en)	1994-12-30	1996-12-17	Nanosystems L.L.C.	Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5560932A (en)	1995-01-10	1996-10-01	Nano Systems L.L.C.	Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en)	1995-01-10	1997-09-02	Nanosystems L.L.C.	Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en)	1995-01-10	1997-09-09	Nanosystems L.L.C.	Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5569448A (en)	1995-01-24	1996-10-29	Nano Systems L.L.C.	Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en)	1995-02-14	1996-10-01	Nawosystems L.L.C.	Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en)	1995-02-06	1996-11-05	Nano Systems L.L.C.	Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en)	1995-02-08	1996-04-02	Eastman Kodak Company	Isolation of ultra small particles
US5622938A (en)	1995-02-09	1997-04-22	Nano Systems L.L.C.	Sugar base surfactant for nanocrystals
US5534270A (en)	1995-02-09	1996-07-09	Nanosystems Llc	Method of preparing stable drug nanoparticles
US5518738A (en)	1995-02-09	1996-05-21	Nanosystem L.L.C.	Nanoparticulate nsaid compositions
US5591456A (en)	1995-02-10	1997-01-07	Nanosystems L.L.C.	Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en)	1995-02-13	1996-11-12	Nano Systems L.L.C.	Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en)	1995-02-14	1996-04-23	Nanosystems Llc	Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en)	1995-02-15	1996-12-03	Nano Systems L.L.C.	Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5718919A (en)	1995-02-24	1998-02-17	Nanosystems L.L.C.	Nanoparticles containing the R(-)enantiomer of ibuprofen
US5747001A (en)	1995-02-24	1998-05-05	Nanosystems, L.L.C.	Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en)	1995-02-24	1996-10-15	Nanosystems L.L.C.	Polyalkylene block copolymers as surface modifiers for nanoparticles
KR100384979B1 (ko)	1995-09-07	2003-10-17	에프. 호프만-라 로슈 아게	심부전증및신부전증치료용의신규한4-(옥시알콕시페닐)-3-옥시-피페리딘
WO1998035666A1 (en)	1997-02-13	1998-08-20	Nanosystems Llc	Formulations of nanoparticle naproxen tablets
CA2291157A1 (en)	1997-05-29	1998-12-03	Eli Lilly And Company	Process for preparing heterocyclic compounds
AU3716499A (en)	1998-04-21	1999-11-08	Aventis Pharma Limited	Substituted diamines and their use as cell adhesion inhibitors
US6437146B1 (en)	1998-09-25	2002-08-20	Fujisawa Pharmaceutical Co., Ltd.	Oxazole compounds as prostaglandin e2 agonists or antagonists
GB9826540D0 (en) *	1998-12-02	1999-01-27	Darwin Discovery Ltd	Process
DE60027131D1 (de)	1999-01-06	2006-05-18	Us Gov Health & Human Serv	Inhibitoren für asparagin-proteasen
JP2000302757A (ja)	1999-04-16	2000-10-31	Shiseido Co Ltd	Ｎ−置換ピペリジン誘導体
NZ520588A (en)	2000-03-21	2004-06-25	Smithkline Beecham Corp	Protease inhibitors
US6900329B2 (en)	2001-03-21	2005-05-31	Schering Corporation	MCH antagonists and their use in the treatment of obesity
MXPA04000334A (es)	2001-07-11	2004-09-28	Elan Pharm Inc	Compuestos de alquilamida n-(3-amino-2-hidroxi-propil) substituidos.
EA200400648A1 (ru)	2001-11-08	2005-04-28	Элан Фармасьютикалз, Инк.	N, n'-замещенные производные 1,3-диамино-2-гидроксипропана
TWI332956B (en)	2002-04-26	2010-11-11	Gilead Sciences Inc	Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds
AU2003238046A1 (en)	2002-06-27	2004-01-19	Actelion Pharmaceuticals Ltd	Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease
US7557137B2 (en)	2002-08-05	2009-07-07	Bristol-Myers Squibb Company	Gamma-lactams as beta-secretase inhibitors
EP1537072A1 (en)	2002-09-10	2005-06-08	Pharmacia & Upjohn Company LLC	Substituted aminoethers for the treatment of alzheimer s disease
CA2544573A1 (en)	2003-11-03	2005-06-02	Probiodrug Ag	Combinations useful for the treatment of neuronal disorders
US20070135406A1 (en) *	2003-12-05	2007-06-14	Olivier Bezencon	Diazabicyclononene and tetrahydropyridine derivatives with a new side-chain
US20070093492A1 (en)	2004-03-09	2007-04-26	Weir-Torn Jiaang	Pyrrolidine derivatives
CA2576971A1 (en)	2004-08-20	2006-03-02	Entremed, Inc.	Compositions and methods comprising proteinase activated receptor antagonists
MX2007003858A (es)	2004-10-07	2007-12-11	Vitae Pharmaceuticals Inc	Diaminoalcanos inhibidores de proteasa asparticas.
CA2595986A1 (en) *	2005-01-28	2006-08-03	Actelion Pharmaceuticals Ltd	7-{4-[2-(2,6-dichlor0-4-methylphenoxy)-ethoxy]phenyl}-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amides as inhibitors of renin for the treatment of hypertension
WO2006083924A1 (en) *	2005-02-02	2006-08-10	Vitae Pharmaceuticals, Inc.	1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors
US7585886B2 (en)	2005-05-19	2009-09-08	Astellas Pharma Inc.	Pyrrolidine derivative or salt thereof
TWI411607B (zh)	2005-11-14	2013-10-11	Vitae Pharmaceuticals Inc	天門冬胺酸蛋白酶抑制劑
US7872028B2 (en)	2006-04-05	2011-01-18	Vitae Pharmaceuticals, Inc.	Diaminopropanol renin inhibitors
ATE520690T1 (de)	2006-09-18	2011-09-15	Vitae Pharmaceuticals Inc	Piperidinderivate als renin-inhibitoren
CL2007002689A1 (es)	2006-09-18	2008-04-18	Vitae Pharmaceuticals Inc	Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
EP2167609A1 (en)	2007-06-20	2010-03-31	Vitae Pharmaceuticals, Inc.	Renin inhibitors
US20100160424A1 (en)	2007-06-20	2010-06-24	Baldwin John J	Renin inhibitors
US7773441B2 (en) *	2008-06-18	2010-08-10	Micron Technology, Inc.	Memory malfunction prediction system and method
JP2011525488A (ja)	2008-06-20	2011-09-22	ヴァイティーファーマシューティカルズ，インコーポレイテッド	レニン阻害剤およびその使用方法
US20110112145A1 (en)	2008-06-26	2011-05-12	Nicole Marie Deschamps	Salts Of Methyl 2-((R))-(3-Chlorophenyl)((R)-1-((S)-2-(Methylamino)-3((R)-tetrahydro-2H-Pyran-3-YL)Propylcarbamoyl)Piperidin-3-YL)Methoxy)Ethylcarbamate
AR077692A1 (es)	2009-08-06	2011-09-14	Vitae Pharmaceuticals Inc	Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo

2007
- 2007-09-14 CL CL200702689A patent/CL2007002689A1/es unknown
- 2007-09-17 PE PE2007001252A patent/PE20080843A1/es not_active Application Discontinuation
- 2007-09-17 AR ARP070104098A patent/AR062797A1/es unknown
- 2007-09-17 TW TW096134810A patent/TWI403510B/zh not_active IP Right Cessation
- 2007-09-18 RS RS20130064A patent/RS52679B/sr unknown
- 2007-09-18 CN CN2007800391198A patent/CN101528723B/zh not_active Expired - Fee Related
- 2007-09-18 NZ NZ575803A patent/NZ575803A/en not_active IP Right Cessation
- 2007-09-18 ES ES07838381T patent/ES2400009T7/es active Active
- 2007-09-18 CA CA002663263A patent/CA2663263A1/en not_active Withdrawn
- 2007-09-18 SI SI200731161T patent/SI2074108T1/sl unknown
- 2007-09-18 AU AU2007297729A patent/AU2007297729C1/en not_active Ceased
- 2007-09-18 HR HRP20130144TT patent/HRP20130144T4/hr unknown
- 2007-09-18 DK DK07838381.7T patent/DK2074108T3/da active
- 2007-09-18 MX MX2009002740A patent/MX2009002740A/es active IP Right Grant
- 2007-09-18 US US12/311,012 patent/US8198453B2/en not_active Expired - Fee Related
- 2007-09-18 PT PT78383817T patent/PT2074108E/pt unknown
- 2007-09-18 KR KR1020097007791A patent/KR20090064582A/ko not_active Ceased
- 2007-09-18 BR BRPI0718460-3A patent/BRPI0718460A2/pt not_active IP Right Cessation
- 2007-09-18 WO PCT/US2007/020164 patent/WO2008036247A1/en not_active Ceased
- 2007-09-18 EP EP07838381.7A patent/EP2074108B3/en active Active
- 2007-09-18 PL PL07838381T patent/PL2074108T6/pl unknown
- 2007-09-18 JP JP2009528331A patent/JP5331695B2/ja not_active Expired - Fee Related
- 2007-09-18 EP EP11186691.9A patent/EP2581366A1/en not_active Withdrawn
2012
- 2012-05-11 US US13/469,562 patent/US8580823B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU2007297729C1 (en)	2012-02-02
CA2663263A1 (en)	2008-03-27
CN101528723A (zh)	2009-09-09
HRP20130144T4 (hr)	2013-10-25
US8198453B2 (en)	2012-06-12
MX2009002740A (es)	2009-06-26
RS52679B (sr)	2013-06-28
TW200829574A (en)	2008-07-16
EP2074108B3 (en)	2013-06-26
EP2074108B1 (en)	2012-11-21
PL2074108T6 (pl)	2013-11-29
AU2007297729A1 (en)	2008-03-27
US20120225906A1 (en)	2012-09-06
PT2074108E (pt)	2013-03-07
SI2074108T1 (sl)	2013-04-30
WO2008036247A1 (en)	2008-03-27
JP5331695B2 (ja)	2013-10-30
AU2007297729B2 (en)	2011-07-28
US8580823B2 (en)	2013-11-12
NZ575803A (en)	2011-11-25
ES2400009T3 (es)	2013-04-05
HK1129115A1 (en)	2009-11-20
KR20090064582A (ko)	2009-06-19
BRPI0718460A2 (pt)	2013-12-03
EP2074108A1 (en)	2009-07-01
ES2400009T7 (es)	2013-11-18
PL2074108T3 (pl)	2013-05-31
AR062797A1 (es)	2008-12-03
WO2008036247A8 (en)	2008-06-26
DK2074108T3 (da)	2013-03-11
PE20080843A1 (es)	2008-08-11
CN101528723B (zh)	2013-04-10
EP2581366A1 (en)	2013-04-17
JP2010503684A (ja)	2010-02-04
US20090312369A1 (en)	2009-12-17
TWI403510B (zh)	2013-08-01
HRP20130144T1 (en)	2013-03-31

Publication	Publication Date	Title
CL2007002689A1 (es)	2008-04-18	Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
CL2008001994A1 (es)	2008-09-22	Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
CL2007002610A1 (es)	2008-02-01	Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2008000690A1 (es)	2008-09-12	Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
CL2014000504A1 (es)	2014-10-03	Compuestos derivados de pirimidinas condensadas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de la insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades.
CL2008001304A1 (es)	2008-09-22	Compuestos derivados de indol sustituido, inhibidores de la proteina activadora de la 5-lipoxigenasa (flap); composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, enfermedad cardiovascular e inflamacion.
CL2007002708A1 (es)	2008-04-04	Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
CL2007000161A1 (es)	2008-05-30	Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2008000592A1 (es)	2008-09-12	Compuestos derivados de pirrol sustituido, supresores de la secrecion de acidos; composicion farmaceutica; y uso en el tratamiento o profilaxis en enfermedades tales como ulcera peptica, gastritis, esofagitis, entre otras.
CL2007001870A1 (es)	2008-06-13	Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d
CL2008001114A1 (es)	2008-12-19	Compuestos derivados de bencimidazol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como vejiga sobreactiva, dolor, obesidad, convulsiones, entre otras.
CL2007002207A1 (es)	2008-02-01	Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
CL2008001076A1 (es)	2008-10-24	Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008000899A1 (es)	2009-02-20	Compuestos derivados de 3-imidazolil-indolilo, inhibidores de la interaccion entre p53 y mdm2 y/o mdm4; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades proliferativas.
CL2009000349A1 (es)	2010-02-19	Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2013003598A1 (es)	2014-07-11	Compuestos derivados de benzooxazepinona, moduladores de canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades seleccionadas de arritmias, insuficiencia cardiaca, angina, infarto al miocardio, diabetes, entre otras
CL2007002327A1 (es)	2008-05-16	Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc.
CL2007002513A1 (es)	2008-04-04	Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
CL2008000875A1 (es)	2008-10-03	Compuestos derivados de imidazolidin-2-ona; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades tales como dislipidemia, diabetes, enfermedades inflamatorias, entre otras.
CL2007000806A1 (es)	2008-05-30	Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008001157A1 (es)	2008-11-03	Compuestos derivados de quinolina-carboxamida, antagonistas de p2y12; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; composicion de una combinacion de dichos compuestos; y uso del compuesto en el tratamiento de trastornos cardiovasculares, tromboembolismo, infarto agudo al miocardio.
CL2009000402A1 (es)	2010-03-05	Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
CL2011000846A1 (es)	2011-09-30	Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2007003672A1 (es)	2008-07-25	Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
CL2007003038A1 (es)	2008-06-06	Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.